United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $474.65, for a total value of $10,679,625.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $470.95, for a total transaction of $10,596,375.00.
• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total transaction of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total transaction of $3,659,197.50.
• On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total value of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $514.35, for a total value of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total value of $11,166,750.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $473.20 on Wednesday. The stock’s 50-day moving average is $486.59 and its 200 day moving average is $430.69. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99. The firm has a market cap of $20.38 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 2.52 and a beta of 0.85.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Lido Advisors LLC boosted its holdings in United Therapeutics by 12.0% during the 4th quarter. Lido Advisors LLC now owns 644 shares of the biotechnology company’s stock worth $314,000 after acquiring an additional 69 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of United Therapeutics by 247.9% in the fourth quarter. Sivia Capital Partners LLC now owns 2,105 shares of the biotechnology company’s stock valued at $1,026,000 after purchasing an additional 1,500 shares during the last quarter. CIBC Asset Management Inc lifted its position in shares of United Therapeutics by 30.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,116 shares of the biotechnology company’s stock valued at $1,031,000 after purchasing an additional 490 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of United Therapeutics by 27.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 110,774 shares of the biotechnology company’s stock valued at $53,975,000 after purchasing an additional 23,938 shares in the last quarter. Finally, Westpac Banking Corp purchased a new position in United Therapeutics during the fourth quarter worth about $719,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright increased their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Wells Fargo & Company boosted their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.